While the long term effects have been widely studied, much less is known about acute effects of BPDE-DNA adducts in Previous studies indicated a high affinity of the transcripcells. In vitro studies have amply demonstrated that BPDEtion factor Sp1 for DNA adducts derived from benzo[a]-DNA adducts represent strong blocks to the progression of pyrene diol epoxide (BPDE) in sequences that are not both DNA polymerase and RNA polymerase (12) (13) (14) (15) . Thus, normal binding sites for Sp1. We tested for functional inhibition of both replication and transcription by unrepaired effects of this phenomenon in three systems in which adducts in the template DNA is expected in BPDE-treated transcription is Sp1-dependent. In an in vitro, Sp1-dependcells. Recently, the formation of BPDE-DNA adducts in tumor ent transcription system addition of heterologous plasmid cells has been correlated with an increase in nuclear levels of DNA containing BPDE adducts abolished production of a the protein product of the damage-inducible p53 gene (16) .
specific run-off transcript. This inhibition was not seen
Although not directly shown for BPDE damage, the induction with unmodified plasmid DNA, and could be overcome by of p53 by other forms of DNA damage results in growth addition of purified Sp1 protein. In SL2 insect cells, higharrest, mediated by the cyclin-dependent kinase inhibitor, CIP1/ level expression of an Sp1-dependent reporter gene, which was dependent on co-transfection of an Sp1 expression WAF1 (17) . This growth arrest is presumed to allow extra vector, was inhibited Ͼ95% by co-transfection of heterotime for repair of DNA adducts prior to replication. The logous DNA containing BPDE adducts. This inhibition mechanism by which BPDE treatment increases cellular p53 could be partially overcome by increasing the amount of levels is unknown. the Sp1 expression vector in the transfections. In human
We have previously shown that the nearly-ubiquitous tran-C33A cells, expression of a transfected reporter gene driven scriptional activator protein, Sp1, has a high affinity for DNA by a GC box containing fragment of the human E2F1 containing BPDE adducts (18) . Sp1 binding to BPDE-damaged promoter was enhanced by co-transfection of an Sp1 DNA does not require the consensus sequence for specific Sp1 expression plasmid. Expression was inhibited 3-6-fold by binding, the GC box. In fact, BPDE adducts placed siteco-transfection of heterologous DNA containing BPDEspecifically in a GC box sequence do not enhance binding of DNA adducts. A similar inhibition was seen in human Sp1 to that sequence and in some cases abolish Sp1 binding SAOS-2 cells, which lack functional p53 protein. These data (19) . Following the previous suggestion of Essigmann and are consistent with functionally significant sequestration of colleagues for cisplatin-DNA adducts (20) , we suggested that the Sp1 transcription factor by BPDE-DNA adducts in all the formation of BPDE adducts in non-GC box sequences in three systems. 
Materials and methods

Materials
Plasmids were prepared by standard molecular biological methods. pGAZ-18 has been described (18) ; it contains a 94 nt region of the fourth exon of the hamster adenosine phosphoribosyl transferase gene inserted into the pGEM3- (27) .
1.0 µg modified pGAZ-18 DNA ϩ 50 ng purified Sp1 (lane 4). Transcript levels are indicated above the lanes, relative to levels in the reaction Modification of DNA containing 1.0 µg unmodified pGAZ-18 DNA (lane 2). Purified pGAZ-18 DNA was modified with racemic BPDE as previously described (18) .
In vitro transcription assay
Results
In vitro transcription assays were performed with HeLa cell nuclear extracts
Effects of BPDE-DNA adducts on Sp1-dependent transcrip-
prepared by the procedure of Shapiro et al. (28). Sp1-depleted HeLa cell nuclear extract was prepared as described by Jackson and Tjian (29) . Run-off tion in vitro transcription conditions were the same as described previously (22) . The
We previously described an in vitro, Sp1-dependent transcriptranscription mixture (25 µl final volume) contained 20 mM Hepes, pH 7.9, tion system that utilizes a recombinant template for RNA Similar levels of inhibition were obtained with preparations of pGAZ-18 DNA that were modified to levels as low as 1% of the nucleotides. The basal level of expression in the absence reaction mixtures might be expected to partially restore tranof the Sp1 expression vector was also inhibited by modified scription. Figure 1C again illustrates the inhibition of transcript pGAZ-18, decreasing from~8200 RLU in the absence of production by inclusion of BPDE-modified heterologous DNA modified DNA to 120 RLU in the presence of 5 µg BPDEin the reaction mixture (compare lane 3 with lane 2). In this modified DNA. experiment, specific transcription was inhibited by~50%.
These data are consistent with the possibility that heteroHowever, the further addition of 50 ng of purified Sp1 protein logous BPDE-DNA adducts introduced into SL2 cells seques-(lane 4) completely restored production of the 180 nucleotide tered Sp1 protein produced by the expression vector pPacSp1, transcript. These data are consistent with the sequestration thus blocking expression. We tested this suggestion by comechanism proposed above.
transfecting increasing amounts of the pPacSp1 vector in an Effects of BPDE-DNA adducts on gene expression in insect attempt to overproduce Sp1 protein and overcome the inhibicells tion. Cotransfection of increasing amounts of pPacSp1 enhanced expression of the pODClux1 vector in the presence The insect cell line, SL2, lacks detectable Sp1-like activity, and transfection of plasmids that are Sp1-dependent into SL2 of either unmodified (Figure 3 , open bars) or BPDE-modified ( Figure 3 , closed bars) pGAZ-18 DNA. Maximal luciferase cells results in low levels of expression. Cotransfection of an exogenous Sp1 expression vector will activate transcription expression was seen with 0.1 µg pPacSp1 in the presence of unmodified pGAZ-18 DNA, and decreased substantially with from an Sp1-dependent promoter (26) . We constructed an expression vector, pODClux1, in which expression of the higher levels of pPacSp1. This may be due to 'squelching' (32) , that is competition between the two expression vectors, firefly luciferase gene is driven by a fragment of the rat ornithine decarboxylase gene that contains five consensus GC pPacSp1 and pODClux1, for limiting components of the general transcription machinery. In contrast, expression in the boxes, and is highly regulated by exogenous Sp1 in SL2 cells (24, 25) . Transfection of pODClux1 alone into SL2 cells led presence of BPDE-modified DNA continued to increase with increasing concentrations of pPacSp1 (Figure 3 , closed bars). to luciferase expression levels below 1ϫ10 4 RLU. As shown in Figure 2 , a high level of expression of pODClux1 was
The inhibition of expression of pODClux1 by the BPDEmodified heterologous DNA relative to expression in the obtained when the Sp1 expression vector pPacSp1 was cotransfected into SL2 cells(Ͼ3ϫ10 6 RLU with no added BPDEpresence of unmodified DNA is shown in Figure 3 by the open circles. At low and intermediate levels of pPacSp1, modified DNA). Co-transfection of pGAZ-18 DNA, previously expression of luciferase in the presence of BPDE-modified pGAZ-18 DNA was 40-80% lower than expression in the presence of unmodified pGAZ-18 DNA. However, at the highest level of pPacSp1 tested (0.3 µg) there was only~10% inhibition of expression by the modified DNA relative to the control (Figure 3, open circles) . These data suggest that increased expression of Sp1 in the SL2 cells can partially overcome the inhibition of pODClux1 expression that occurs upon co-transfection with BPDE-modified DNA.
Effects of BPDE-DNA adducts on gene expression in human cells
The promoter region of the human gene for the cell cycleregulated transcription factor E2F1 contains several GC box motifs, and at least one of these sites is necessary for transcription of the gene (27) . A reporter plasmid (E2F1LUC) containing a portion of this promoter driving the luciferase gene is active upon transfection into a variety of human cells. Co-transfection of a CMV-Sp1 expression plasmid in human C33A cells enhanced luciferase activity~2.5-fold (data not shown), suggesting that the reporter plasmid is Sp1-responsive. When increasing amounts of BPDE-modified, heterologous pGAZ-18 plasmid DNA were co-transfected with E2F1LUC, very clear dose-dependent inhibition of expression was seen ( Figure 4A , closed circles). The maximal inhibition seen in a number of experiments was 80-90%. This inhibition was due to the BPDE-DNA adducts since the total amount of pGAZ-18 DNA was kept constant in all transfections by adding the appropriate amount of mock-modified DNA. Similar results were seen with an expression vector in which E2F binding sites in the E2F1 promoter had been removed ( Figure 4A , closed triangles). Expression vectors in which the bacterial β-galactosidase gene is driven by either RSV or CMV sequences were also included in all transfections. Interestingly, expression of β-galactosidase was also inhibited by the presence of modified pGAZ-18 DNA in the transfection mixtures ( Figure 4A , open circles), although to a lesser extent than with the E2F1 promoter-driven luciferase vectors.
The formation of BPDE-DNA adducts in cells is known to increase levels of the p53 gene product (16) . Although there are no data showing such an induction in cells transfected with BPDE-modified DNA, it seemed possible that the results obtained in C33A cells were due to a generalized inhibition of transcription or to an apoptotic response mediated by p53. We therefore repeated the experiments in the SAOS-2 cell line are partially depleted by the presence of heterologous DNA containing BPDE-DNA adducts. This is consistent with a of Sp1 binding to BPDE adducts at illegitimate (i.e. non-GC partial 'highjacking' of Sp1 and possibly other transcription box) sites (18, 19) suggested that a similar phenomenon might factors by the BPDE-DNA adducts.
occur with this ubiquitous transcription factor. The current results represent the first evidence that these illegitimate Discussion binding phenomena have functional consequences. In each of the systems chosen, the expression of an Sp1-dependent gene The suggestion that carcinogen-DNA adducts might functionally 'highjack' transcription factors was originally made by construct was studied in the presence and absence of BPDE adducts added in trans. Because the adducts were located in Essigman and colleagues (20) , based on binding of human upstream binding factor to cisplatin adducts. Our demonstration heterologous DNA and not in the expression vector itself, direct effects of the adducts on the template function of the may be severely disrupted in cells following acute exposure to BPDE. Such acute disregulation may be a contributor to expressed DNA can be excluded. In each system, BPDE adducts added in trans to the Sp1-dependent expression conthe initiation process of carcinogenesis, acting in parallel with the more widely recognized mutational pathway associated struct significantly repressed expression. In the in vitro transcription assays, the effect was clearly at the level of with the formation of DNA damage. It is interesting to note a similarity with the mechanisms of action of the small DNA transcription. Furthermore, the ability of purified Sp1 to overcome the inhibition of transcription strongly suggested tumor viruses in transformation, where viral proteins also deregulate gene expression in infected cells. Proteins encoded that binding of Sp1 from the nuclear extract to the heterologous DNA containing BPDE adducts was responsible for the by SV40, adenovirus and some of the human papilloma viruses interact with the protein products of two tumor suppressor repression.
There was also a strong negative effect of the BPDEgenes, Rb and p53, inactivating the proteins. Inactivation of Rb allows inappropriate transcription of S-phase-specific genes modified DNA on gene expression in the cellular transfection assays, both of which utilized Sp1-dependent promoter con- (48) , whereas inactivation of p53 may prevent expression of growth inhibitory genes. Finally, T antigen, encoded by SV40, structs. Inhibition of expression by the heterologous, BPDEmodified DNA was dose-dependent (Figures 2 and 4) , and blocks AP-2-dependent transcription, apparently by direct protein-protein interaction with AP-2 (49). Thus, it seems lowered expression to 10-20% of the controls in both insect and human cells at the higher doses. The fact that inhibition possible that both chemical carcinogens and DNA tumor viruses exhibit subversion of normal gene regulation as one was also seen in SAOS-2 cells, which lack functional p53, argues that the effect was not due to an overall shutdown of facet of their oncogenic actions. For the DNA tumor viruses, integration into the cellular transcription by a p53-mediated process, either cell cycle arrest or induction of apoptosis (34) . Based on the in vitro data, it genome and continued production of the subversive proteins provides the long-term persistence of the disruption of gene seems likely that at least part of the effect was mediated by functional sequestration of Sp1. This is especially true in the regulation needed for transformation. Because carcinogen-DNA adducts are efficiently removed from the genome by insect cells where there was a dramatic increase in reporter gene expression upon cotransfection of the Sp1 expression DNA repair systems, epigenetic mechanisms for the 'fixation' of any deregulation of gene expression must be envisioned if vector, and this increase was inhibited by modified DNA.
The presence of BPDE-modified DNA also interfered with the effects we have described are to contribute in a long-term way to neoplastic transformation. It was long ago realized that basal expression in the insect cells and with β-galactosidase expression in human cells using vectors in which transcription positive feedback loops can provide such a mechanism (50), and specific examples of such epigenetic mechanisms have was driven by the RSV or CMV promoters. One possible explanation is that other transcription factors, either specific recently been proposed (51, 52) . Biological examples of such feedback loops can be found in abundance in the developmental or general, may also be subject to the inhibitory effects of BPDE adducts. Indeed, we have recently found an increased biology literature (52) , and the cell-cycle regulatory genes E2F1 and cyclin E appear to constitute a positive feedback binding of the E2F1-and E2F4-DP1 transcription factor complexes to BPDE-modified DNA (A.Coleman, D.Johnson, loop (27, 53, 54) . It remains to be determined whether carcinogen-DNA adducts perturb the functioning of these or other K.L.Powell, and M.C.MacLeod, in preparation). Alternatively, the apparent inhibition of the viral promoters may be due to regulatory systems in a way that can lead to heritable changes in gene expression. sequestration of Sp1. The RSV promoter has been reported to be Sp1-responsive (35) and examination of the CMV promoter sequence (36) reveals multiple GC-and GT-boxes upstream
